Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 2094788
Author(s) Ferrins, Lori; Rahmani, Raphaël; Sykes, Melissa L.; Jones, Amy J.; Avery, Vicky M.; Teston, Eliott; Almohaywi, Basmah; Yin, Jiexiang; Smith, Jason; Hyland, Chris; White, Karen L.; Ryan, Eileen; Campbell, Michael; Charman, Susan A.; Kaiser, Marcel; Baell, Jonathan B.
Author(s) at UniBasel Kaiser, Marcel
Year 2013
Title 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis
Journal European journal of medicinal chemistry
Volume 66
Pages / Article-Number 450-465
Keywords 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides, Human African trypanosomiasis, Sleeping sickness, Trypanosomacidal agent, Trypanosoma brucei
Abstract A whole organism high-throughput screen of approximately 87,000 compounds against Trypanosoma brucei brucei led to the recent discovery of several novel compound classes with low micromolar activity against this organism and without appreciable cytotoxicity to mammalian cells. Herein we report a structure-activity relationship (SAR) investigation around one of these hit classes, the 3-(oxazolo[4,5-b]pyridin-2-yl)anilides. Sharp SAR is revealed, with our most active compound (5) exhibiting an IC50 of 91 nM against the human pathogenic strain T.b. rhodesiense and being more than 700 times less toxic towards the L6 mammalian cell line. Physicochemical properties are attractive for many compounds in this series. For the most potent representatives, we show that solubility and metabolic stability are key parameters to target during future optimisation.
Publisher Elsevier
ISSN/ISBN 0223-5234
edoc-URL http://edoc.unibas.ch/dok/A6165196
Full Text on edoc No
Digital Object Identifier DOI 10.1016/j.ejmech.2013.05.007
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/23831695
Document type (ISI) Article
 
   

MCSS v5.8 PRO. 0.316 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
14/05/2024